Sobuzoxane
e)(ester) · Sobuzoxane · Perazoline · Sobuzoxane/MST 16 · methylpropyl)ester · 1,2-bis(4-isobutoxycarbonyloxymethyl-3,5-dioxo-piperazin-1-yl)ethane · 4,4’-ethylenebis(1-(hydroxymethyl)-2,6-piperazinedione)bis(isobutylcarbonat · 1,2-ethanediylbis((2,6-dioxo-4,1-piperazinediyl)methylene)bis(2-carbonicaci
Identifikatoren & physikalische Daten
| CAS No. | 98631-95-9 |
|---|---|
| Summenformel | C22H34N4O10 |
| Durchschnittliche Molmasse | 514,5 g/mol |
| Monoisotopische Masse | 514,22749329 g/mol |
| SMILES | CC(C)COC(=O)OCN1C(=O)CN(CCN2CC(=O)N(COC(=O)OCC(C)C)C(=O)C2)CC1=O |
| InChIKey | OCOKWVBYZHBHLU-UHFFFAOYSA-N |
| PubChem CID | 5233 |
| ChEMBL | CHEMBL1256871 |
| ChEBI | CHEBI:32136 |
| DTXSID | DTXSID5045203 |
Chemische & physikalische Eigenschaften
| XLogP | 2 |
|---|---|
| Polarare Oberfläche (TPSA) | 152 |
| H-Brücken-Donoren | 0 |
| H-Brücken-Akzeptoren | 12 |
| Frei drehbare Bindungen | 15 |
| Schwere Atome | 36 |
| Formalladung | 0 |
| Komplexität | 743 |
| Schmelzpunkt | 128-130°mp 132-133° (Cai, 1989) |
| Siedepunkt | 664.9±55.0 °C(Predicted) |
| Dichte | 1.272±0.06 g/cm3(Predicted) |
| Löslichkeit | DMSO: 19 mg/mL |
| Aggregatzustand | solid |
| pKa (Säurekonstante) | 2.75±0.20(Predicted) |
| Farbe | White to off-white |
Sicherheit & Vorschriften
| Wassergefährdungsklasse (WGK) | 2 |
|---|---|
| RTECS-Nr. | FG1582500 |
| Toxizität | LD50 in male, female mice, rats (mg/kg): 807, 960, 877, 567 i.p.400, 673, 3025, 2821 s.c.>5 g/kg orally in all species (Tokiwa) |
Anwendungen & Verwendung
Beschreibung
Sobuzoxane, a novel bis(2,6-dioxopiperazine) derivative, was introduced in Japan for the treatment of malignant lymphoma and adult T-cell IeukemiaQmphoma (ATLL), which is resistant to chemotherapy and has a poor prognosis. Sobuzoxane exhibits 8 broad spectrum of antitumor activity. It is a noncleavable complexstabilizing topoisomerase II inhibitor and exerts its function via interfering with the catalytic activity of the enzyme to result in an irreversible inhibition of cell division by blockade of chromosome condensation and segregation. Due to Its unique mode of cytocidai activity, it has no cross resistance with many currently available anticancer agents. Sobuzoxane is reported to significantly inhibit growth of human colon, lung, gastric, and breast cancers and is in clinical trials for these indications.
Verwenden
Sobuzoxane is an inhibitor of DNA topoisomerase II which induces apoptosis.